Cargando…

Novel cancer therapy targeting microbiome

In the human intestinal tract, there are more than 100 trillion symbiotic bacteria, which form the gut microbiota. Approximately 70% of the human immune system is in the intestinal tract, which prevents infection by pathogenic bacteria. When the intestinal microbiota is disturbed, causing dysbiosis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagano, Tatsuya, Otoshi, Takehiro, Hazama, Daisuke, Kiriu, Tatsunori, Umezawa, Kanoko, Katsurada, Naoko, Nishimura, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526180/
https://www.ncbi.nlm.nih.gov/pubmed/31190864
http://dx.doi.org/10.2147/OTT.S207546
_version_ 1783419847802093568
author Nagano, Tatsuya
Otoshi, Takehiro
Hazama, Daisuke
Kiriu, Tatsunori
Umezawa, Kanoko
Katsurada, Naoko
Nishimura, Yoshihiro
author_facet Nagano, Tatsuya
Otoshi, Takehiro
Hazama, Daisuke
Kiriu, Tatsunori
Umezawa, Kanoko
Katsurada, Naoko
Nishimura, Yoshihiro
author_sort Nagano, Tatsuya
collection PubMed
description In the human intestinal tract, there are more than 100 trillion symbiotic bacteria, which form the gut microbiota. Approximately 70% of the human immune system is in the intestinal tract, which prevents infection by pathogenic bacteria. When the intestinal microbiota is disturbed, causing dysbiosis, it can lead to obesity, diabetes mellitus, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, autism spectrum disorder and cancer. Recent metabolomics analyses have also made the association between the microbiota and carcinogenesis clear. Here, we review the current evidence on the association between the microbiota and gastric, bladder, hepatobiliary, pancreatic, lung and colorectal cancer. Moreover, several animal studies have revealed that probiotics seem to be effective for the prevention of carcinogenesis to some extent. In this review, we focused on this relationship between the microbiota and cancer, and considered how to prevent cancer using strategies involving the gut microbiota.
format Online
Article
Text
id pubmed-6526180
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65261802019-06-12 Novel cancer therapy targeting microbiome Nagano, Tatsuya Otoshi, Takehiro Hazama, Daisuke Kiriu, Tatsunori Umezawa, Kanoko Katsurada, Naoko Nishimura, Yoshihiro Onco Targets Ther Review In the human intestinal tract, there are more than 100 trillion symbiotic bacteria, which form the gut microbiota. Approximately 70% of the human immune system is in the intestinal tract, which prevents infection by pathogenic bacteria. When the intestinal microbiota is disturbed, causing dysbiosis, it can lead to obesity, diabetes mellitus, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, autism spectrum disorder and cancer. Recent metabolomics analyses have also made the association between the microbiota and carcinogenesis clear. Here, we review the current evidence on the association between the microbiota and gastric, bladder, hepatobiliary, pancreatic, lung and colorectal cancer. Moreover, several animal studies have revealed that probiotics seem to be effective for the prevention of carcinogenesis to some extent. In this review, we focused on this relationship between the microbiota and cancer, and considered how to prevent cancer using strategies involving the gut microbiota. Dove 2019-05-13 /pmc/articles/PMC6526180/ /pubmed/31190864 http://dx.doi.org/10.2147/OTT.S207546 Text en © 2019 Nagano et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Nagano, Tatsuya
Otoshi, Takehiro
Hazama, Daisuke
Kiriu, Tatsunori
Umezawa, Kanoko
Katsurada, Naoko
Nishimura, Yoshihiro
Novel cancer therapy targeting microbiome
title Novel cancer therapy targeting microbiome
title_full Novel cancer therapy targeting microbiome
title_fullStr Novel cancer therapy targeting microbiome
title_full_unstemmed Novel cancer therapy targeting microbiome
title_short Novel cancer therapy targeting microbiome
title_sort novel cancer therapy targeting microbiome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526180/
https://www.ncbi.nlm.nih.gov/pubmed/31190864
http://dx.doi.org/10.2147/OTT.S207546
work_keys_str_mv AT naganotatsuya novelcancertherapytargetingmicrobiome
AT otoshitakehiro novelcancertherapytargetingmicrobiome
AT hazamadaisuke novelcancertherapytargetingmicrobiome
AT kiriutatsunori novelcancertherapytargetingmicrobiome
AT umezawakanoko novelcancertherapytargetingmicrobiome
AT katsuradanaoko novelcancertherapytargetingmicrobiome
AT nishimurayoshihiro novelcancertherapytargetingmicrobiome